MCID: VSC008
MIFTS: 35

Vascular Hemostatic Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Hemostatic Disease

MalaCards integrated aliases for Vascular Hemostatic Disease:

Name: Vascular Hemostatic Disease 12 15
Vascular Hemostatic Disorders 73
Hemostatic Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:484
MeSH 44 D020141
SNOMED-CT 68 21112004
UMLS 73 C0600502

Summaries for Vascular Hemostatic Disease

MalaCards based summary : Vascular Hemostatic Disease, also known as vascular hemostatic disorders, is related to thrombophilia due to activated protein c resistance and thrombophilia due to protein c deficiency, autosomal dominant. An important gene associated with Vascular Hemostatic Disease is KRIT1 (KRIT1, Ankyrin Repeat Containing), and among its related pathways/superpathways are Selenium Micronutrient Network and Formation of Fibrin Clot (Clotting Cascade). The drugs Warfarin and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include endothelial, pituitary and brain, and related phenotypes are embryo and nervous system

Wikipedia : 76 Hemostasis or haemostasis is a process which causes bleeding to stop, meaning to keep blood within a... more...

Related Diseases for Vascular Hemostatic Disease

Diseases related to Vascular Hemostatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 thrombophilia due to activated protein c resistance 31.7 F2 F3
2 thrombophilia due to protein c deficiency, autosomal dominant 10.9
3 thrombophilia, x-linked, due to factor ix defect 10.9
4 thrombophilia due to protein c deficiency, autosomal recessive 10.9
5 thrombophilia due to protein s deficiency, autosomal dominant 10.9
6 heparin cofactor ii deficiency 10.9
7 thrombophilia due to histidine-rich glycoprotein deficiency 10.9
8 antithrombin iii deficiency 10.9
9 protein z deficiency 10.9
10 thrombophilia due to thrombomodulin defect 10.9
11 intracranial structure hemangioma 10.3 KRIT1 SNRPB
12 brain angioma 10.3 KRIT1 SNRPB
13 cerebral angioma 10.3 KRIT1 SNRPB
14 hemangioma of intra-abdominal structure 10.2 HBA1 KRIT1
15 bone epithelioid hemangioma 10.2 F3 HBA1
16 drug-induced lupus erythematosus 10.2 F12 HBA1
17 cloacogenic carcinoma 10.2 F12 HBA1
18 cavernous malformation 10.2 CCM2 KRIT1
19 intracranial embolism 10.2 F12 F2
20 cerebral falx meningioma 10.2 F2 F3
21 leech infestation 10.2 F2 F3
22 prothrombin deficiency 10.2 F2 F3
23 human venous malformation 10.2 CCM2 KRIT1
24 intestinal impaction 10.2 F2 F3
25 fournier gangrene 10.2 F2 F3
26 cerebral sinovenous thrombosis 10.2 F2 F3
27 qualitative platelet defect 10.2 F2 F3
28 giant hemangioma 10.2 F2 F3
29 sagittal sinus thrombosis 10.2 F2 F3
30 blue toe syndrome 10.2 F2 F3
31 femoral neuropathy 10.2 F2 F3
32 alcohol-related birth defect 10.2 F2 F3
33 factor xii deficiency 10.2 F12 F3
34 hantavirus pulmonary syndrome 10.2 F2 F3
35 von willebrand disease, type 1 10.2 F2 F3
36 anterior cranial fossa meningioma 10.2 F2 F3
37 korean hemorrhagic fever 10.2 F2 F3
38 marantic endocarditis 10.2 F2 F3
39 splenic disease 10.2 F2 F3
40 purpura fulminans 10.2 F2 F3
41 hepatic infarction 10.2 F2 F3
42 peripheral vertigo 10.2 F2 F3
43 inherited blood coagulation disease 10.2 F2 F3
44 blood coagulation disease 10.2 F2 F3
45 blood protein disease 10.1 F2 F3
46 hemophilia 10.1 F2 F3
47 endocardium disease 10.1 F2 F3
48 klippel-trenaunay-weber syndrome 10.1 CCM2 KRIT1
49 branch retinal artery occlusion 10.1 F2 F3
50 analbuminemia 10.1 F2 F3

Graphical network of the top 20 diseases related to Vascular Hemostatic Disease:



Diseases related to Vascular Hemostatic Disease

Symptoms & Phenotypes for Vascular Hemostatic Disease

MGI Mouse Phenotypes related to Vascular Hemostatic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.43 CCM2 CR1L F2 F3 KRIT1 TNF
2 nervous system MP:0003631 9.23 CCM2 CR1L F12 F2 F3 KRIT1

Drugs & Therapeutics for Vascular Hemostatic Disease

Drugs for Vascular Hemostatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 804)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
2
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 4053 460612
3
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
10
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
11
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 1197-18-8 5526
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
13
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
14
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
19
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
20
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6 772 46507594
21
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
22
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
23
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
24
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
25
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
26
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
27
Apixaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 503612-47-3 10182969
28
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
29
Daratumumab Approved Phase 4,Phase 2,Phase 3,Phase 1 945721-28-8
30
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
31
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
32 fluindione Approved, Investigational Phase 4 957-56-2
33
Phenindione Approved, Investigational Phase 4 83-12-5 4760
34
Phytonadione Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84-80-0 4812 5284607
35
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
36
Celiprolol Approved, Investigational Phase 4 56980-93-9
37
Phentolamine Approved Phase 4 50-60-2 5775
38
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
39
Protein C Approved Phase 4,Phase 3
40 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
41
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
42
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
43
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
44 Edoxaban Approved Phase 4,Phase 2,Phase 3 480449-70-5
45
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-45-1 5951
46
Menadione Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 58-27-5 4055
47
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
48
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 31703
49
Pirarubicin Investigational Phase 4 72496-41-4
50
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7

Interventional clinical trials:

(show top 50) (show all 2945)
# Name Status NCT ID Phase Drugs
1 Clinical and Economic Implications of Genetic Testing for Warfarin Management Unknown status NCT00964353 Phase 4 Warfarin
2 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
3 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
4 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
5 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
6 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
7 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
8 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
9 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes Completed NCT00738023 Phase 4 Rosiglitazone;Normal saline 0.9%;Intralipid 20%
10 Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial Completed NCT02864875 Phase 4 Fibrinogen concentrate
11 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
12 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
13 Octaplas Pediatric Plasma Replacement Trial Completed NCT02050841 Phase 4
14 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
15 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
16 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
17 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
18 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
19 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
20 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
21 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
22 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
23 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
24 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
25 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
26 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
27 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
28 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
29 Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type Completed NCT00190411 Phase 4 celiprolol;Control
30 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
31 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
32 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
33 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
34 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
35 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
36 Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
37 Human Fibrinogen Concentrate in Pediatric Cardiac Surgery Recruiting NCT02822599 Phase 4 RiaStAP;Saline
38 Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal Recruiting NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
39 CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients Recruiting NCT02777424 Phase 4 Prothrombin Complex Concentrate
40 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
41 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
42 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
43 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
44 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
45 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
46 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
47 Intranasal Bevacizumab for HHT-Related Epistaxis Recruiting NCT02389959 Phase 4 Bevacizumab;Placebo (Saline)
48 Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo
49 Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period Active, not recruiting NCT03449342 Phase 4 turoctocog alfa
50 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Active, not recruiting NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet

Search NIH Clinical Center for Vascular Hemostatic Disease

Cochrane evidence based reviews: hemostatic disorders

Genetic Tests for Vascular Hemostatic Disease

Anatomical Context for Vascular Hemostatic Disease

MalaCards organs/tissues related to Vascular Hemostatic Disease:

41
Endothelial, Pituitary, Brain, Liver, Bone

Publications for Vascular Hemostatic Disease

Articles related to Vascular Hemostatic Disease:

(show all 11)
# Title Authors Year
1
Hemostatic Disorders in Hormonally Active Pituitary Tumors. ( 26285071 )
2015
2
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. ( 24951423 )
2014
3
[Association of hemostatic disorders in diabetic patients with methylenetetrahydrofolate reductase (C677T) and coagulation factors II (G20210A) and V (G1691A) gene polymorphism]. ( 21574459 )
2011
4
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. ( 19684626 )
2009
5
Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. ( 18001734 )
2008
6
Hemostatic disorders in bird flu infection. ( 18180608 )
2008
7
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]. ( 9499627 )
1998
8
[Recurrent epistaxis in children as an indicator of hemostatic disorders]. ( 9949588 )
1998
9
Hemostatic disorders associated with arterial hypertension and peripheral arterial disease. ( 8522567 )
1995
10
[The Willebrand factor in the diagnosis of hemostatic disorders in patients with rheumatoid arthritis]. ( 1710721 )
1991
11
[Characteristics of hemostatic disorders in septic shock in children]. ( 2396772 )
1990

Variations for Vascular Hemostatic Disease

Expression for Vascular Hemostatic Disease

Search GEO for disease gene expression data for Vascular Hemostatic Disease.

Pathways for Vascular Hemostatic Disease

GO Terms for Vascular Hemostatic Disease

Cellular components related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 F12 F2 F3 HBA1 KRIT1 TNF
2 extracellular region GO:0005576 9.17 CFHR4 CR1L F12 F2 F3 HBA1

Biological processes related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.54 F12 F2 F3
2 negative regulation of endothelial cell proliferation GO:0001937 9.4 KRIT1 TNF
3 fibrinolysis GO:0042730 9.32 F12 F2
4 blood coagulation, intrinsic pathway GO:0007597 9.26 F12 F2
5 positive regulation of blood coagulation GO:0030194 9.16 F12 F2
6 regulation of blood coagulation GO:0030193 8.96 F12 F2
7 hemostasis GO:0007599 8.8 F12 F2 F3

Molecular functions related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 8.8 F12 F2 F3

Sources for Vascular Hemostatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....